This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developingRNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). It is expected to expedite the development of a wide range of new therapeutics using the small non-coding area of the genome that is not explored.
OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The post How did pharma develop a vaccine so quickly?
Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. According to Bumcrot, regRNAs are “RNAs that arise out of the non-coding genome”. Their platform identifies which regRNAs control the specific gene of interest.
Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. The post Verge Genomics takes AI-sourced drug for ALS into clinic appeared first on.
GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics.
The act also created an industry that didn’t exist in the United States before its enactment, enabling the formation of companies to develop and commercialize therapies for rare diseases. That said, a lot has changed in science and drug development since 1983. The human genome was sequenced in 2003.
In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research. The Power of Single Cell Technology.
Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA. The system comprises the Cas9 enzyme and a guide RNA.
Ocean Genomics Partners With Geninus to Co-DevelopRNA-Based Biomarkers and Advance Research Ocean Genomics Partners With Geninus to Co-DevelopRNA-Based Biomarkers and Advance Research PITTSBURGH–(BUSINESS WIRE)–#RNA–Ocean Genomics (Pittsburgh, PA), a world leader in AI-based gene expression analysis and RNA biomarker … Continue (..)
The collaboration aims to “close the gap between single-cell RNA sequencing wet-lab services and single-cell data analysis solutions,” which will allow scientists to study the finest details that can be hard to access. Developments in the sector have already led to significant scientific breakthroughs.
The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible. The post 2nd RNA Editing Summit 2020 appeared first on. Visit our website: www.rna-editing-summit.com.
10X Genomics just agreed to acquire ReadCoor, Inc., The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology. an innovator in the nascent field of in situ technology.
Genome sequencing has historically been classified into DNA sequencing and RNA sequencing. DNA sequencing generates data that is very robust, reproducible, insightful, and can be applied to genes having different expression level by selecting genomic region. between 2022 and 2035.
Researchers at the Hong Kong University of Science and Technology (HKUST) developed a novel technology which allows genomic DNA and RNA sequencing to be carried out simultaneously in single cells of both frozen and fresh tissues, and identified rare brain tumor cell "spies" disguised as normal cells with this method.
Mpro has become the main focus of intense research and treatment development as it is vital for viral replication. These smaller segments can subsequently fold and develop to create new virus particles. It functions as a molecular scissor by slicing long chains of virus’ polypeptide proteins into smaller component proteins.
Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Moderna will also assume further development, manufacturing, and commercialisation responsibilities on exercising a target option.
TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR). Abbott Spinal Cord Stimulation (SCS) Systems Manufacturer/developer : Abbott Medical Date of FDA approval : May 30, 2024 Approved for : Chronic, hard-to-manage pain in the torso, arms and legs.
UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas. fundraiser in July for the next stage of its development. That restructure was accompanied by a £1.6
Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018. The aim will be to identify promising candidates in areas of “unmet patient need.”
Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to fine-tune the expression of genes. ” The post CAMP4 raises $100m to take lead RNA drugs into clinic appeared first on. .
As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players.
The team also found that the oral compound, RG7834, developed by Hoffmann-La Roche, hindered replication at a crucial step, preventing the virus from infecting liver cells. HAV usually hijacks TENT4 and utilises it for the replication of its own genome.
In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.
Singapore scientists uncover potential role of long non-coding RNAs in pancreatic cancer Credit: From Figure 4 in Liu, S., Genome Med 12, 89 (2020). doi:10.1186/s13073-020-00788-5… SINGAPORE, 3 Nov 2020 – Long RNA molecules carrying DNA codes that […]. Harmston, N., Glaser, T.L.
A new stem cell model, discovered by researchers exploring the human genome, will help scientists to map out the key genomic changes during early development. Prior to this latest development, research into the human ZGA was limited to human embryos at a later stage of growth, under stringent UK regulations.
Developed by MIT researchers Jonathan Gootenberg and Omar Abudayyeh, PASTE (Programmable Addition via Site-specific Targeting Elements) gene editing technology can insert genes as long as 36,000 DNA base pairs to liver cells in mice as well as several types of human cells. How does the Gene Editing Tool PASTE Work?
CRISPR is notable for engineering living cells, allowing scientists to edit, turn off, delete, or replace genes in a cell’s genome. It is difficult to control where the viral vectors insert genes in the genome, and it is difficult to manufacture large quantities of clinical-grade viral vectors.
While ARV-based treatments work well to keep the virus suppressed and patients healthy — some for many years — resistance to one or more drugs in a treatment regimen can develop in some patients. HIV drug resistance occurs when virions develop mutations that make them less susceptible to given drugs. HIV Drug Resistance Testing.
RNA sequencing and novel machine learning algorithms generate a test that improves lung cancer diagnosis using brushings from the main lung airway SOUTH SAN FRANCISCO, Calif.–(BUSINESS Nasdaq: VCYT) today announced the publication of a manuscript detailing the development … Continue reading →
ADARx bags USD 75 Million to advance its RNA tech pipeline. ADARx Pharmaceuticals, a biotechnology company developingRNA targeting therapeutics , announced the completion of a USD 75 million Series B financing to progress its drug development pipeline. SR One Capital Management and OrbiMed Advisors co-led Series B.
At the end of May, we hosted a webinar titled “ Changing Times, Changing Therapies: Keeping Up with Advancements in Cell and Gene Therapies ” to provide a quick update on the latest advancements and ongoing in development of these advanced therapeutics. Clinical holds are becoming more common, especially in gene therapy programs.
Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.
which developsgenome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. .–( BUSINESS WIRE )– EdiGene, Inc. as Head of the US Subsidiary, and Kehua Fan, M.D.,
Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma.
In the paper, researchers from Johns Hopkins University and elsewhere found a natural long-form transactivating CRISPR RNA (tracr-L) in Streptococcus pyogenes that functions to downregulate its endogenous CRISPR-Cas9 system. But altering the tracr-L with genetic engineering to make it function more like a guide RNA increased CRISPR-Cas9 cuts.
NGS has emerged as an evolutionary technology in modern biotechnology and healthcare research, enabling researchers to develop a better understanding of the cause and consequences of disease. Currently, close to 60 industry players are actively offering NGS kits for preparing DNA / RNA libraries. Players Engaged in the Domain.
It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases. Furthermore, these drug candidates can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies.
Accenture Applied Intelligence announced a new data and analytics approach to manage and derive insights from paediatric acute myeloid leukaemia (AML) genomic data, with the potential to improve precision medicine.
Insights from project could potentially improve precision medicine use for paediatric AML.
The heart-1 study is enrolling patients with an inherited form of very high cholesterol – heterozygous familial hypercholesterolaemia (HeFH) – that predisposes them to early development of heart disease. — Sek Kathiresan MD (@skathire) July 12, 2022. They are administered every two to four weeks, depending on LDL cholesterol response.
Peer stated that his team plans to develop a treatment for all cancers and that their technique could be ready for humans within the next two years. CTX001 is being developed under a co-development and co-commercial agreement between the two organizations. Once the DNA has been cut, the cell’s natural repair mechanisms kick in.
Molecular diagnostic tests are advanced techniques and tools used to analyze biological markers in the genome and proteome. Molecular diagnostic tests refer to tests intended to detect specific sequences in human genomic samples, such as DNA or RNA, in order to diagnose a particular disease. What are Molecular Diagnostic Tests?
. “Innovation in cancer treatment is realized through collaboration, and the physicians and researchers at Emory’s Winship Cancer Institute have consistently shown their commitment to developing novel cancer therapies using this collaborative approach,” said Chadi Nabhan , M.D., Ramalingam , M.D.,
Genomic data from the phase II CUPISCO study in Cancer of Unknown Primary (CUP), an uncommon type of cancer with high unmet need, could support diagnostics and more personalised treatment plans. Roche’s Chief Medical Officer and Head of Global Product Development. Lung Cancer Highlights.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content